Filibuvir

From WikiMD.org
Jump to navigation Jump to search

Filibuvir

Filibuvir (pronounced: /fiːliːbjuːvɪr/) is an experimental antiviral drug that is being studied for the treatment of Hepatitis C. It is a non-nucleoside polymerase inhibitor that was developed by Pfizer.

Etymology

The name "Filibuvir" is derived from the Latin words filum meaning "thread" and buvir which is a short form of "buccal virus", referring to the drug's mechanism of action against viral replication.

Mechanism of Action

Filibuvir works by inhibiting the RNA-dependent RNA polymerase, an enzyme that is essential for the replication of the hepatitis C virus. By blocking this enzyme, Filibuvir prevents the virus from multiplying in the body.

Clinical Trials

Filibuvir has been tested in several clinical trials for its efficacy and safety in patients with chronic hepatitis C. In a Phase 2 trial, Filibuvir was found to be well-tolerated and showed promising antiviral activity.

Related Terms

See Also

External links

Esculaap.svg

This WikiMD dictionary article is a stub. You can help make it a full article.


Languages: - East Asian 中文, 日本, 한국어, South Asian हिन्दी, Urdu, বাংলা, తెలుగు, தமிழ், ಕನ್ನಡ,
Southeast Asian Indonesian, Vietnamese, Thai, မြန်မာဘာသာ, European español, Deutsch, français, русский, português do Brasil, Italian, polski